<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17380">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880631</url>
  </required_header>
  <id_info>
    <org_study_id>360051-001</org_study_id>
    <nct_id>NCT02880631</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ In Resistant Hypertension</brief_title>
  <official_title>BAROSTIM THERAPY™ In Resistant Hypertension: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM
      NEO System in the commercial setting in subjects recently implanted under the CE-Marked
      indication for resistant hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Blood Pressure Changes from Baseline to 6 Months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Medication Changes from Baseline to 6 Months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>Medication name, dose, frequency, and start/stop date will be assessed over the 6 month time interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalizations over Follow-Up</measure>
    <time_frame>12 months post-implant</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Barostim Neo™ System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects can be included in the Hypertension Registry if they were implanted in the past
        30 days and meet the CE-Mark approved indications and contraindications for the BAROSTIM
        NEO System in the treatment of resistant hypertension.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has signed an EC approved informed consent form

          -  Has been implanted with the BAROSTIM NEO system in the past 30 days

          -  Systolic blood pressure greater than or equal to 140 mmHg, and

          -  Resistance to maximally tolerated therapy with a diuretic and two other
             anti-hypertension medications

        Exclusion Criteria:

          -  Bilateral carotid bifurcations located above the level of the mandible

          -  Baroreflex failure or autonomic neuropathy

          -  Uncontrolled, symptomatic cardiac bradyarrhythmias

          -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation
             to be greater than 50%

          -  Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannes Reuter, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Herzzentrum Uniklinik Köln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CVRx Vice President of Clinical Research</last_name>
    <phone>763-416-2876</phone>
  </overall_contact>
  <location>
    <facility>
      <name>St. Josefs-Hospital Cloppenburg gemainnutzige gGmbH</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Venneklaas</last_name>
      <phone>+49 4471-16 2955</phone>
      <email>ulla.venneklaas@kk-om.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Luders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Dietrich</last_name>
      <phone>+49 (341) 97 12 408</phone>
      <email>jenny.dietrich@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Janine Starke</last_name>
      <phone>+49 (341) 97 12 443f</phone>
      <email>janine.starke@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Neef</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital and MVS Maria-Hilf Stadtlohn GmbH</name>
      <address>
        <city>Stadtlohn</city>
        <zip>489703</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Fitz</last_name>
      <phone>02563-912-6370</phone>
      <email>b.fitz@kmh-stadtlohn.de</email>
    </contact>
    <investigator>
      <last_name>Alessandro Cuneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Landkreis Tuttlingen</name>
      <address>
        <city>Tuttlingen</city>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weber Ida</last_name>
      <phone>07461 97 1415</phone>
      <email>i.weber@klinikum-tut.de</email>
    </contact>
    <investigator>
      <last_name>Michael Kotzerke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010 Oct 5;56(15):1254-8. doi: 10.1016/j.jacc.2010.03.089.</citation>
    <PMID>20883933</PMID>
  </reference>
  <reference>
    <citation>Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 9;58(7):765-73. doi: 10.1016/j.jacc.2011.06.008.</citation>
    <PMID>21816315</PMID>
  </reference>
  <reference>
    <citation>Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr;6(2):152-8. doi: 10.1016/j.jash.2012.01.003.</citation>
    <PMID>22341199</PMID>
  </reference>
  <reference>
    <citation>Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012 Jul-Aug;6(4):270-6. doi: 10.1016/j.jash.2012.04.004. Epub 2012 Jun 12.</citation>
    <PMID>22694986</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 21, 2017</lastchanged_date>
  <firstreceived_date>August 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
